These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 1869595)

  • 1. A comparison of the metabolic effects of flosequinan and propranolol in patients with non-insulin-dependent diabetes mellitus.
    Lewis HM; Kendall MJ; Wright AD; Bratty JR; Maxwell S
    J Clin Pharm Ther; 1991 Jun; 16(3):161-6. PubMed ID: 1869595
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison of the effects of flosequinan, a new vasodilator, and propranolol on sub-maximal exercise in healthy volunteers.
    Lewis HM; Kendall MJ; Smith SR; Bratty JR
    Br J Clin Pharmacol; 1989 May; 27(5):547-52. PubMed ID: 2757879
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of flosequinan and nifedipine on glucose tolerance in healthy volunteers.
    Lewis H; Kendall M; Bratty JR
    J Clin Pharm Ther; 1988 Aug; 13(4):269-72. PubMed ID: 3235476
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Flosequinan does not affect systemic and regional vascular responses to simulated orthostatic stress in healthy volunteers.
    Duranteau J; Pussard E; Edouard A; Samii K; Berdeaux A; Giudicelli JF
    Br J Clin Pharmacol; 1992 Sep; 34(3):207-14. PubMed ID: 1389945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of flosequinan on autonomic tone in congestive heart failure: implications for the mechanism of the positive chronotropic effect and survival influence of long-term vasodilator administration.
    Binkley PF; Nunziata E; Cody RJ
    Am Heart J; 1994 Dec; 128(6 Pt 1):1147-56. PubMed ID: 7985595
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beta-blockers in hypertensive non-insulin-dependent diabetics: comparison between penbutolol and propranolol on metabolic control and response to insulin-induced hypoglycemia.
    Marengo C; Marena S; Renzetti A; Mossino M; Pagano G
    Acta Diabetol Lat; 1988; 25(2):141-8. PubMed ID: 3066086
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A double blind study of the effect of acipimox on serum lipids, blood glucose control and insulin action in non-obese patients with type 2 diabetes mellitus.
    Fulcher GR; Catalano C; Walker M; Farrer M; Thow J; Whately-Smith CR; Alberti KG
    Diabet Med; 1992 Dec; 9(10):908-14. PubMed ID: 1478035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hemodynamic and neurohormonal effects of flosequinan in patients with heart failure.
    Isnard R; Lechat P; Pousset F; Carayon A; Kalotka H; Chikr H; Salloum J; Thomas D; Komajda M
    Fundam Clin Pharmacol; 1997; 11(1):83-9. PubMed ID: 9182081
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Double-blind, placebo-controlled study of the efficacy of flosequinan in patients with chronic heart failure. Principal Investigators of the REFLECT Study.
    Packer M; Narahara KA; Elkayam U; Sullivan JM; Pearle DL; Massie BM; Creager MA
    J Am Coll Cardiol; 1993 Jul; 22(1):65-72. PubMed ID: 8509565
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of effects of quinapril and metoprolol on glycaemic control, serum lipids, blood pressure, albuminuria and quality of life in non-insulin-dependent diabetes mellitus patients with hypertension. Swedish Quinapril Group.
    Ostman J; Asplund K; Bystedt T; Dahlöf B; Jern S; Kjellström T; Lithell H
    J Intern Med; 1998 Aug; 244(2):95-107. PubMed ID: 10095796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of flosequinan on regional blood flow in normal man.
    Scott RA; Woods KL; Barnett DB
    Br J Clin Pharmacol; 1991 Jan; 31(1):41-6. PubMed ID: 2015169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Can further benefit be achieved by adding flosequinan to patients with congestive heart failure who remain symptomatic on diuretic, digoxin, and an angiotensin converting enzyme inhibitor? Results of the flosequinan-ACE inhibitor trial (FACET).
    Massie BM; Berk MR; Brozena SC; Elkayam U; Plehn JF; Kukin ML; Packer M; Murphy BE; Neuberg GW; Steingart RM
    Circulation; 1993 Aug; 88(2):492-501. PubMed ID: 8339411
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Flosequinan in chronic heart failure: how is exercise capacity improved?
    Banning AP; Ramsey MW; Jones EA; Evans W; Carolan G; Jones CH; Henderson AH
    Eur J Clin Pharmacol; 1996; 51(2):133-8. PubMed ID: 8911877
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insulin versus glipizide treatment in patients with non-insulin-dependent diabetes mellitus. Effects on blood pressure and glucose tolerance.
    Levy J; Vandenberg M; Grunberger G
    Am J Hypertens; 1995 May; 8(5 Pt 1):445-53. PubMed ID: 7662219
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-Term Effects of Flosequinan on the Morbidity and Mortality of Patients With Severe Chronic Heart Failure: Primary Results of the PROFILE Trial After 24 Years.
    Packer M; Pitt B; Rouleau JL; Swedberg K; DeMets DL; Fisher L
    JACC Heart Fail; 2017 Jun; 5(6):399-407. PubMed ID: 28501522
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Positive inotropy contributes to the hemodynamic mechanism of action of flosequinan (BTS 49465) in the intact dog.
    Greenberg S; Touhey B
    J Cardiovasc Pharmacol; 1990 Jun; 15(6):900-10. PubMed ID: 1694912
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of concurrent administration of flosequinan and digoxin on the pharmacokinetics of each drug.
    Rau R; Hind ID; Wynne RD; White SA
    Arzneimittelforschung; 1994 Mar; 44(3):300-4. PubMed ID: 8192694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cumulative hemodynamic response to short-term treatment with flosequinan (BTS 49465), a new direct-acting vasodilator drug, in severe chronic congestive heart failure.
    Kessler PD; Packer M; Medina N; Yushak M
    J Cardiovasc Pharmacol; 1988 Jul; 12(1):6-11. PubMed ID: 2459536
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial.
    Maggs DG; Buchanan TA; Burant CF; Cline G; Gumbiner B; Hsueh WA; Inzucchi S; Kelley D; Nolan J; Olefsky JM; Polonsky KS; Silver D; Valiquett TR; Shulman GI
    Ann Intern Med; 1998 Feb; 128(3):176-85. PubMed ID: 9454525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. A randomized, controlled trial.
    Giugliano D; Acampora R; Marfella R; De Rosa N; Ziccardi P; Ragone R; De Angelis L; D'Onofrio F
    Ann Intern Med; 1997 Jun; 126(12):955-9. PubMed ID: 9182472
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.